Research analysts at Leerink Partners initiated coverage on shares of Erasca (NASDAQ:ERAS – Get Free Report) in a research report issued to clients and investors on Tuesday, Benzinga reports. The firm set an “outperform” rating and a $35.00 price target on the stock. Leerink Partners‘s price target suggests a potential upside of 142.90% from the stock’s previous close.
Several other brokerages have also commented on ERAS. Morgan Stanley boosted their price objective on Erasca from $12.00 to $21.00 and gave the stock an “equal weight” rating in a report on Monday, July 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Erasca in a research note on Tuesday, September 8th. HC Wainwright lifted their target price on shares of Erasca from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, August 12th. Guggenheim boosted their price target on shares of Erasca from $20.00 to $21.00 and gave the stock a “buy” rating in a research note on Thursday, August 13th. Finally, Bank of America boosted their price target on shares of Erasca from $18.00 to $20.00 and gave the stock a “neutral” rating in a research note on Friday, August 14th. Nine research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $23.17.
View Our Latest Analysis on Erasca
Erasca Price Performance
NASDAQ ERAS traded down $0.70 during trading on Tuesday, reaching $14.41. The company’s stock had a trading volume of 1,266,914 shares, compared to its average volume of 5,804,983. The stock has a market capitalization of $5.04 billion, a PE ratio of -14.59 and a beta of 0.68. The firm has a fifty day moving average of $14.94 and a 200 day moving average of $15.28. Erasca has a one year low of $2.71 and a one year high of $24.28.
Erasca (NASDAQ:ERAS – Get Free Report) last released its quarterly earnings results on Thursday, November 12th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Research analysts expect that Erasca will post -0.49 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Erasca
A number of hedge funds and other institutional investors have recently modified their holdings of ERAS. Goldman Sachs Group Inc. raised its holdings in shares of Erasca by 13.8% during the 3rd quarter. Goldman Sachs Group Inc. now owns 4,348,033 shares of the company’s stock valued at $63,742,000 after buying an additional 525,920 shares in the last quarter. Soleus Capital Management L.P. boosted its stake in Erasca by 89.3% in the third quarter. Soleus Capital Management L.P. now owns 5,112,000 shares of the company’s stock worth $74,942,000 after buying an additional 2,412,000 shares in the last quarter. Integral Health Asset Management LLC boosted its stake in Erasca by 13.0% in the third quarter. Integral Health Asset Management LLC now owns 1,130,000 shares of the company’s stock worth $16,566,000 after buying an additional 130,000 shares in the last quarter. Jump Financial LLC purchased a new stake in Erasca in the third quarter worth approximately $1,774,000. Finally, Empowered Funds LLC bought a new position in Erasca during the third quarter valued at approximately $165,000. 67.78% of the stock is currently owned by hedge funds and other institutional investors.
Recent Erasca Headlines
These are some of the ERAS headlines that stood out recently:
- Positive Sentiment: Erasca will present updated Phase 1 data for ERAS-0015 at a virtual investor event on November 20. The company says early dose-escalation results showed favorable safety and tolerability, with partial responses in several patients, including at low doses. These are preliminary clinical findings, and the event may be a near-term catalyst. Erasca investor event and Phase 1 update
- Positive Sentiment: The company also highlighted promising preclinical results for ERAS-4001, its investigational pan-KRAS inhibitor, adding potential longer-term pipeline upside. The findings are preclinical and do not establish clinical benefit. Erasca investor event announcement
- Negative Sentiment: HC Wainwright cut its EPS forecasts, including FY2026 to a loss of $0.54 per share from $0.51, and reduced its FY2027–FY2030 estimates substantially. The firm nevertheless maintained its Buy rating and $22 price target, which may partly offset the concern over wider projected losses. Erasca analyst coverage
Erasca Company Profile
Erasca, Inc. is a clinical-stage biotechnology company focused on developing medicines for cancer. Its research centers on the RAS/MAPK signaling pathway, which is involved in the growth of many tumors and can be difficult to target with existing therapies. The company’s pipeline includes investigational drug candidates designed to inhibit RAS proteins and other targets in the pathway. Erasca evaluates these candidates for potential use across multiple cancer types; its medicines remain in development rather than being marketed as approved treatments.
Further Reading
- Five stocks we like better than Erasca
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
- Tyson Foods’ Earnings Beat Hides a Warning for Consumer Staples Dividend Investors
- 3 Stocks in an Overlooked Corner of Infrastructure With Hundreds of Billions at Stake
Receive News & Ratings for Erasca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erasca and related companies with MarketBeat.com's FREE daily email newsletter.
